Uncategorised - European Medical Journal

Continue
First Comprehensive Map of Ovarian Cell Types
1 Mins
10th March 2020

First Comprehensive Map of Ovarian Cell Types

A COMPLETE cell map of the human ovary has been generated, which may direct future developments in fertility management and assisted reproduction…
Pregnancy Duration Changes Newborn DNA
1 Mins
10th March 2020

Pregnancy Duration Changes Newborn DNA

DURATION of pregnancy has been linked with chemical DNA changes in newborns and may direct future understandings in the care of premature infants…
10th March 2020

An Interview with Prof Jonathan Sackier at the International Colorectal Disease Symposium 2020

Spencer Gore, CEO of EMG-Health, speaks to Professor Jonathan Sackier at the International Colorectal Disease Symposium in Israel about EMG-Health…
4 Mins
6th March 2020

Expert Update for Doctors on COVID-19: A Summary of the Event

A point of concern also highlighted by Prof Maria Zambon is poor preparedness for such an outbreak in low-resource settings. Certain countries in Africa…
London
10 Mins
3rd March 2020

A Change for Better Exchange – From Membrane Therapeutic Plasma Exchange to Centrifugal Therapeutic Plasma Exchange

Plasmapheresis is an extracorporeal procedure in which plasma is separated from the cellular components of the blood and then either donated or discarded…
Balkan Endemic Nephropathy Linked to Contaminated Groundwater - Image
1 Mins
2nd March 2020

Balkan Endemic Nephropathy Linked to Contaminated Drinking Water

A UNIQUE type of endemic kidney disease, originating in farming villages located along the Danube River in Balkan countries, is now thought…
Benefits of Eliminating Prehydration Prior to CT Scans for Patients with Chronic Kidney Disease - Image
1 Mins
2nd March 2020

Benefits of Eliminating Prehydration Prior to CT Scans for Patients with Chronic Kidney Disease

THE SAFETY and cost-effectiveness of not giving prehydration to patients with chronic kidney disease (CKD) prior to a CT scan has been preliminary…
9 Mins
28th February 2020

Biologics in Moderate-to-Severe Psoriasis: Discover the Road to Long-term Control

Advances in the treatment of moderate-to-severe psoriasis have accelerated considerably in the last 30 years. Prof Piaserico provided an overview of the…
8 Mins
28th February 2020

Tildrakizumab in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analyses on Efficacy, Time to Relapse, Long-Term Safety in Elderly Population and Predictability From The reSURFACE 1 and reSURFACE 2 Phase III Clinical Trials

Psoriasis is a chronic, relapsing inflammatory skin disease, characterised in most cases by sharply demarcated, erythematous, pruritic plaques covered…
4 Mins
28th February 2020

Long-Term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis through 3 Years (148 Weeks) from reSURFACE 1 and reSURFACE 2 Phase III Trials

IL-23 plays a key regulatory role in the pathogenesis of plaque psoriasis and medications targeting IL-23 have been shown to be effective for people with…